Effects of anti-inflammatory therapy on bursting pressure of colonic anastomosis in murine dextran sulfate sodium induced colitis

References

• Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum 2000;43:1141–5.
   PubMed Web of Science ®Google Scholar
• Alves A, Panis Y, Trancart D, Regimbeau JM, Pocard M, Valleur P. Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients. World J Surg 2002;26:499–502.
   PubMed Web of Science ®Google Scholar
• Myrelid P, Olaison G, Sjödahl R, Nyström PO, Almer S, Andersson P. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn’s disease. Dis Colon Rectum 2009;52:1387–94.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009:CD000067.
   PubMed Web of Science ®Google Scholar
• Myrelid P, Olaison G, Sjödahl R, Nyström P-O, Almer S, Andersson P. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn’s disease. Dis Colon Rectum 2009;52:1387–94.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Loftus EVJr, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311–16.
   PubMed Web of Science ®Google Scholar
• Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320–7.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EVJr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878–83.
   PubMed Web of Science ®Google Scholar
• Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn’s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003;134:565–72; discussion 572-3.
   PubMed Web of Science ®Google Scholar
• Marchal L, D’Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–54.
   PubMed Web of Science ®Google Scholar
• Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730–6; discussion 1736-1737.
   PubMed Web of Science ®Google Scholar
• Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg 2008;12:1738–44.
   PubMed Web of Science ®Google Scholar
• Zmora O, Khaikin M, Pishori T, Pikarsky A, Dinnewitzer A, Weiss EG, et al. Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives? Int J Colorectal Dis 2007;22:289–92.
   Google Scholar
• Ferrante M, D’Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062–70.
   PubMed Web of Science ®Google Scholar
• Myrelid P, Marti-Gallostra M, Ashraf S, Sunde ML, Tholin M, Øresland T, et al. Complications in surgery for Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg 2014;101:539–45.
   PubMed Web of Science ®Google Scholar
• Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694–702.
   PubMed Web of Science ®Google Scholar
• Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:1328–38.
   PubMed Web of Science ®Google Scholar
• Medina C, Santana A, Paz MC, Diaz-Gonzalez F, Farre E, Salas A, et al. Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol 2006;79:954–62.
   PubMed Web of Science ®Google Scholar
• Björck S, Jennische E, Dahlström A, Ahlman H. Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats. Dig Dis Sci 1997;42:824–32.
   PubMedGoogle Scholar
• Hirotani Y, Mikajiri K, Ikeda K, Myotoku M, Kurokawa N. Changes of the peptide YY levels in the intestinal tissue of rats with experimental colitis following oral administration of mesalazine and prednisolone. Yakugaku Zasshi 2008;128:1347–53.
   Google Scholar
• Pelissier MA, Muller C, Hill M, Morfin R. Protection against dextran sodium sulfate-induced colitis by dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat. Steroids 2006;71:240–8.
   PubMedGoogle Scholar
• Melgar S, Karlsson L, Rehnstrom E, Karlsson A, Utkovic H, Jansson L, et al. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol 2008;8:836–44.
   PubMedGoogle Scholar
• Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999;13:251–60.
   PubMed Web of Science ®Google Scholar
• Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107:353–8.
   PubMed Web of Science ®Google Scholar
• Melgar S, Bjursell M, Gerdin AK, Svensson L, Michaelsson E, Bohlooly YM. Mice with experimental colitis show an altered metabolism with decreased metabolic rate. Am J Physiol Gastrointest Liver Physiol 2007;292:165–72.
   Google Scholar
• van Meeteren ME, Meijssen MA, Zijlstra FJ. The effect of dexamethasone treatment on murine colitis. Scand J Gastroenterol 2000;35:517–21.
   PubMed Web of Science ®Google Scholar
• Månsson P, Zhang XW, Jeppsson B, Thorlacius H. Anastomotic healing in the rat colon: comparison between a radiological method, breaking strength and bursting pressure. Int J Colorectal Dis 2002;17:420–5.
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385–91.
   PubMed Web of Science ®Google Scholar
• Agwunobi AO, Carlson GL, Anderson ID, Irving MH, Scott NA. Mechanisms of intestinal failure in Crohn’s disease. Dis Colon Rectum 2001;44:1834–7.
   Google Scholar
• Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011;140:221–30.
   PubMed Web of Science ®Google Scholar
• Mantzoros I, Kanellos I, Demetriades H, Christoforidis E, Kanellos D, Pramateftakis MG, et al. Effects of steroid on the healing of colonic anastomoses in the rat. Tech Coloproctol 2004;8:180–3.
   Google Scholar
• Del Rio JV, Beck DE, Opelka FG. Chronic perioperative steroids and colonic anastomotic healing in rats. J Surg Res 1996;66:138–42.
   Google Scholar
• Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008;103:2373–81.
   PubMed Web of Science ®Google Scholar
• Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1–9.
   PubMed Web of Science ®Google Scholar
• Polat A, Nayci A, Polat G, Aksoyek S. Dexamethasone down-regulates endothelial expression of intercellular adhesion molecule and impairs the healing of bowel anastomoses. Eur J Surg 2002;168:500–6.
   Google Scholar
• Nagaoka T, Kaburagi Y, Hamaguchi Y, Hasegawa M, Takehara K, Steeber DA, et al. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. Am J Pathol 2000;157:237–47.
   PubMed Web of Science ®Google Scholar
• Eubanks TR, Greenberg JJ, Dobrin PB, Harford FJ, Gamelli RL. The effects of different corticosteroids on the healing colon anastomosis and cecum in a rat model. Am Surg 1997;63:266–9.
   Google Scholar
• Stolzenburg T, Ljungmann K, Christensen H. The effect of azathioprine on anastomotic healing: an experimental study in rats. Dis Colon Rectum 2007;50:2203–8.
   Google Scholar
• Ågren MS, Andersen TL, Andersen L, Schiodt CB, Surve V, Andreassen TT, et al. Nonselective matrix metalloproteinase but not tumor necrosis factor-alpha inhibition effectively preserves the early critical colon anastomotic integrity. Int J Colorectal Dis 2011;26:329–37.
   Google Scholar
• Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006;93:793–9.
   PubMedGoogle Scholar
• Myrelid P, Söderholm JD, Olaison G, Sjödahl R, Andersson P. Split stoma in resectional surgery of high risk patients with ileocolonic Crohn’s disease. Colorectal Dis 2012;14:188–93.
   PubMed Web of Science ®Google Scholar
• Hendriks T, Mastboom WJ. Healing of experimental intestinal anastomoses. Parameters for repair. Dis Colon Rectum 1990;33:891–901.
   PubMed Web of Science ®Google Scholar
• Komen N, de Bruin RW, Kleinrensink GJ, Jeekel J, Lange JF. Anastomotic leakage, the search for a reliable biomarker. A review of the literature. Colorectal Dis 2008;10:109–15; discussion 115-117.
   Google Scholar
• Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest 2011;121:1722–32.
   PubMed Web of Science ®Google Scholar
• Deshpande N, Lutz AM, Ren Y, Foygel K, Tian L, Schneider M, et al. Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US. Radiology 2012;262:172–80.
   Google Scholar
• Lopetuso LR, Petito V, Cufino V, Arena V, Stigliano E, Gerardi V, et al. Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. Dig Liver Dis 2013;45:1017–21.
   Google Scholar
• Flores MB, Rocha GZ, Damas-Souza DM, Osorio-Costa F, Dias MM, Ropelle ER, et al. Obesity-induced increase in tumor necrosis factor-alpha leads to development of colon cancer in mice. Gastroenterology 2012;143:741–53; e1-4.
   Google Scholar
• Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006;281:13964–71.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2000;(2):CD000545.
   Google Scholar
• Shen C, de Hertogh G, Bullens DM, Van Assche G, Geboes K, Rutgeerts P, et al. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis 2007;13:308–16.
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2004:CD003574.
   Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grannö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619–35.
   PubMed Web of Science ®Google Scholar
• Fredin MF, Ulfhammer E, Rhedin M, Melgar S, Mellgard B, Peterson A. Anti-inflammatory effects of budesonide in intestinal epithelial cells. Pharmacol Res 2005;52:422–8.
   Google Scholar
• Chakrabarti S, Patel KD. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J Leukoc Biol 2005;78:279–88.
   Web of Science ®Google Scholar
• Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005;26:379–90.
   PubMedGoogle Scholar
• Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005;129:1991–2008.
   PubMed Web of Science ®Google Scholar
• Esposito E, Mazzon E, Riccardi L, Caminiti R, Meli R, Cuzzocrea S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008;45:166–73.
   PubMed Web of Science ®Google Scholar
• Garg P, Rojas M, Ravi A, Bockbrader K, Epstein S, Vijay-Kumar M, et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 2006;177:4103–12.
   PubMed Web of Science ®Google Scholar
• Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G175–84.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112–24.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis 2010;4:28–62.
   PubMed Web of Science ®Google Scholar